Evidence map›Paper›PMID 30060141›Full record

ArticleHuman molecular genetics2018

ADAMTS10-mediated tissue disruption in Weill-Marchesani syndrome.

Ewa J Mularczyk, Mukti Singh, Alan R F Godwin, Francessco Galli, Neil Humphreys, Antony D Adamson, Aleksandr Mironov, Stuart A Cain, Gerhard Sengle, Ray P Boot-Handford and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 56 citations in OpenAlex.

  1. Physiology (Bethesda, Md.) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. A Novel Mutation in theInternational journal of molecular sciences · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Growth plate extracellular matrix defects and short stature in children.Annals of pediatric endocrinology & metabolism · 2022
    Article
  14. Optic neuropathy associated with TGFβ dysregulation in mice with a glaucoma-causative mutation of ADAMTS10.Matrix biology : journal of the International Society for Matrix Biology · 2022
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. O-fucosylation of thrombospondin type 1 repeats is essential for ECM remodeling and signaling during bone development.Matrix biology : journal of the International Society for Matrix Biology · 2022
    Article
  20. Adamts10 controls transforming growth factorFrontiers in molecular biosciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Ewa J MularczykWellcome Centre for Cell Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.
Mukti SinghWellcome Centre for Cell Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.
Alan R F GodwinWellcome Centre for Cell Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.
Francessco GalliDivision of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK.
Neil HumphreysSchool of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK.
Antony D AdamsonSchool of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK.
Aleksandr MironovSchool of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK.
Stuart A CainWellcome Centre for Cell Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.
Gerhard SengleCenter for Biochemistry, Center for Molecular Medicine (CMMC), Medical Faculty, University of Cologne, Germany.
Ray P Boot-HandfordWellcome Centre for Cell Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.
Giulio CossuDivision of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK.
Cay M KieltyWellcome Centre for Cell Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.
Clair BaldockWellcome Centre for Cell Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.
University of Manchester · GBHenry Royce Institute · GBManchester Academic Health Science Centre · GBUniversity of Cologne · DE

Funding

Biotechnology and Biological Sciences Research Council BB/N015398/1Biotechnology and Biological Sciences Research Council BB/R008221/1Medical Research Council MR/L016540/1Wellcome Trust 088785/Z/09/ZWellcome Trust 097820/Z/11/B
6 · The paper itself

Abstract

Fibrillin microfibrils are extracellular matrix assemblies that form the template for elastic fibres, endow blood vessels, skin and other elastic tissues with extensible properties. They also regulate the bioavailability of potent growth factors of the TGF-β superfamily. A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)10 is an essential factor in fibrillin microfibril function. Mutations in fibrillin-1 or ADAMTS10 cause Weill-Marchesani syndrome (WMS) characterized by short stature, eye defects, hypermuscularity and thickened skin. Despite its importance, there is poor understanding of the role of ADAMTS10 and its function in fibrillin microfibril assembly. We have generated an ADAMTS10 WMS mouse model using Clustered Regularly Spaced Interspaced Short Palindromic Repeats and CRISPR associated protein 9 (CRISPR-Cas9) to introduce a truncation mutation seen in WMS patients. Homozygous WMS mice are smaller and have shorter long bones with perturbation to the zones of the developing growth plate and changes in cell proliferation. Furthermore, there are abnormalities in the ciliary apparatus of the eye with decreased ciliary processes and abundant fibrillin-2 microfibrils suggesting perturbation of a developmental expression switch. WMS mice have increased skeletal muscle mass and more myofibres, which is likely a consequence of an altered skeletal myogenesis. These results correlated with expression data showing down regulation of Growth differentiation factor (GDF8) and Bone Morphogenetic Protein (BMP) growth factor genes. In addition, the mitochondria in skeletal muscle are larger with irregular shape coupled with increased phospho-p38 mitogen-activated protein kinase (MAPK) suggesting muscle remodelling. Our data indicate that decreased SMAD1/5/8 and increased p38/MAPK signalling are associated with ADAMTS10-induced WMS. This model will allow further studies of the disease mechanism to facilitate the development of therapeutic interventions.

Indexed as

Disease Models, AnimalMutationSignal TransductionADAMTS ProteinsAnimalsMAP Kinase Signaling SystemMiceMice, TransgenicMicrofibrilsSmad Proteins, Receptor-RegulatedWeill-Marchesani SyndromeADAMTS10 protein, mouseADAMTS ProteinsSmad Proteins, Receptor-Regulated

Identifiers

PMID30060141
PMCPMC6196651
OpenAlexW2884043390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.